Post by miamianne67 on Mar 3, 2017 2:35:19 GMT
The following posts from today have been cut and pasted from another section because Uncle has now created this Section for similar posts about the hx, trials, travails and brilliant successes of Phillip Frost, MD: Billionaire:
2 hours ago icemandios and thought013 like this ReplyQuoteEditlikePost Options Post by miamianne67 on 2 hours ago
New York Times
Business Day
WORLD U.S. N.Y. / REGION BUSINESS TECHNOLOGY SCIENCE HEALTH SPORTS OPINION ARTS STYLE TRAVEL JOBS REAL ESTATE AUTOS
Search
DealBookMarketsEconomyEnergyMediaTechnologyPersonal TechEntrepreneurshipYour Money
Big Board's Uncovered Short Sales Reach a High
By LAURENCE ZUCKERMAN
Published: August 20, 1994
FACEBOOK
TWITTER
GOOGLE+
EMAIL
SHARE
PRINT
REPRINTS
Correction Appended
Short-selling is the opposite of buying a security in the hope that its price will rise; a short-seller borrows shares, sells them and later buys them back to return to the original owner. If the stock price drops, the trader profits because he can buy back the borrowed shares for less than he sold them. But if the stock rises, the trader loses when shares are repurchased. AT&T and Ford Among Leaders
Companies with the largest short positions on the New York Stock Exchange included RJR Nabisco Holdings, the Ford Motor Company, the AT&T Corporation and the Chrysler Corporation. Ford and AT&T were also among the stocks on the Big Board that showed the greatest monthly rise in short positions.
On the American Stock Exchange, the largest short positions included the Elan Corporation, the Ivax Corporation, XCL Ltd. and Turner Broadcasting System's class B shares.
An increase in short-selling activity has historically been regarded as an indication that stock prices will fall. But in recent years, more investors have used short positions as one element in multifaceted trading strategies. Some analysts even see rising uncovered short-selling positions as a positive sign, since the short-sellers must one day return to the market to buy the shares. Big Activity in Small Stock
The positions most difficult to cover are for those stocks that are sold short widely but are only thinly traded. For example, at the average number of shares traded last month, it would take about 150 trading days to cover the short position of Mark IV Industries, a maker of automotive and office equipment.
Some investors like to buy stocks with high cover ratios because they believe that investors with short positions will bid up the price of the shares when they enter the market to buy back the stock.
Other stocks with high cover ratios included Jan Bell Marketing, Elan and Cincinnati Gas and Electric.
cosomatic1
Full Member
***
cosomatic1 Avatar
Money: $550.00
Posts: 112Male
Posting Level
Next Level in 138 posts
2 hours ago miamianne67, icemandios, and 1 more like this ReplyQuotelikePost Options Post by cosomatic1 on 2 hours ago
I can't imagine who in there right mind would stay short at 7 and change. Thanks for the reminder on IVAX Miami. Good example how Dr. Frost can set them up...
miamianne67
Supreme Member
*****
miamianne67 Avatar
Money: $4,305.00
Posts: 840Female
Member is Online
Posting Level
Next Level in 160 posts
2 hours ago icemandios likes this ReplyQuoteEditlikePost Options Post by miamianne67 on 2 hours ago
Market Place; Expectations Cut, Ivax Drops $5.75
By Kurt Eichenwald
Published: December 22, 1992
FACEBOOK
TWITTER
GOOGLE+
EMAIL
SHARE
PRINT
REPRINTS
AFTER more than a year of lofty promises for the the Ivax Corporation, expectations fell to earth yesterday as investors learned that the company's hot-selling drug was a little cooler than expected.
Ivax, a holding company for pharmaceutical and chemical businesses, was among the biggest losers yesterday on the American Stock Exchange, dropping $5.75 a share to close at $29.25 on volume of almost 1.7 million shares. It was the worst day in the stock's trading in its recent history.
What went wrong? Nothing much, really. There were no fundamental changes in its business or major disasters. Rather, the story behind Ivax's stock drop is one of rosy predications on Wall Street that prove impossible to meet.
While Wall Street frequently makes bad calls about stocks, Ivax is a special case. With the stock trading at some 69 times earnings and having about a $2.3 billion market capitalization at the close of trading on Friday, there was little to support a steep rise in its stock price other than the projection of its future business.
And no one on Wall Street pushed those projections further or harder than Ronald Nordmann, an analyst with Paine Webber, a firm that provides investment banking services to Ivax and whose specialist subsidiary makes a market in the stock. A large number of Wall Street traders and analysts said that no analyst or market participant had had greater influence on investors' attitudes toward Ivax than Mr. Nordmann.
"He has been the biggest bull on Wall Street on this stock," one analyst said. "He's got a pretty large following." A woman answering Mr. Nordmann's telephone yesterday said he was on vacation. He did not return telephone messages that she said had been relayed to him.
Mr. Nordmann worked hard on selling the Ivax story. Analysts say that when the company had troubles, Mr. Nordmann, who has wide respect within the pharmaceutical industry, won praise from his colleagues by being able to line up conference calls quickly between his clients and Ivax's management. That has won him admiration from competitors, investors and the company, none of whose attitudes seem dampened by the fact that Mr. Nordmann has been sued by investors in another stock he recommended who accused him of being over-optimistic.
Indeed, Mr. Nordmann's influence is so great that it was the news that he was cutting his quarterly earnings estimates for Ivax and reducing the company from a "buy" to an "attractive" rating that precipitated yesterday's selloff.
Among the only investors who do not appear to have been shocked by the change were Ivax insiders, who have been selling the stock heavily for months. Last month, almost 200,000 shares were sold by insiders, almost half of the total insider selling at the company for the entire year, according to David Coleman, editor of Vickers Weekly Insider Report. "At these prices, the insiders prefer the cash over the shares," he said.
Mr. Nordmann's overestimation on Ivax came from projections of its potential sales of its generic hypertension drug verapamil, a calcium channel blocker used once a day. The analyst had set goals for $50 million in sales of the drug this year -- higher than other analysts. In an interview in the fall, shortly after shipments began, Mr. Nordmann said that it would be "hard to believe" Ivax could miss that target.
It did. In his analysis yesterday, Mr. Nordmann cut back his estimates of verapamil sales to $40 million, citing long-term supply deals with managed-care organizations reached by G. D. Searle and Knoll, the makers of the brand name version of the drug. Those contracts, which were signed and delivered even before Ivax won approval for its drug, prevent those potential buyers from purchasing verapemil from Ivax.
This is not the first time Mr. Nordmann has been one of the most eager predictors of a company's performance before it disappointed. Both Paine Webber and Mr. Nordmann are still facing a six- year-old lawsuit charging the analyst with making overly positive comments about a stock that subsequently dropped sharply in value.
That lawsuit, filed in 1986, involved a recommendation made by the analyst to buy the stock of ICN Pharmaceuticals, another investment banking client of the firm. The company was testing a treatment for influenza, herpes and AIDS known as virazole, and in his report, Mr. Nordmann said the treatment "could become one of the largest-selling drugs in the world."
Mr. Nordmann's report in 1986 pushed up ICN's price from $18.875 to $33.375 in a week. After news reports at the time questioned his analysis, the stock fell significantly. In 1991, ICN paid $600,000 in costs and penalties after the Food and Drug Administration charged the company with misrepresenting the medicinal qualities of the drug. ICN stock traded yesterday at $6.375.
But Mr. Nordmann does not expect the Ivax story to be similar to that of ICN. In his analysis yesterday, the analyst said he remained "extremely enthusiastic," and that his new projections may prove too low. "We would rather have the opportunity to raise our estimates in the future," he wrote.
A lesson well learned.
Graph: "A Sudden Drop" tracks Ivax Corporation's stock price, monthly closings from 1990 through yesterday.
icemandios
Legendary
*
icemandios Avatar
Money: $16,380.00
Posts: 2,484Male
Posting Level
about an hour ago ReplyQuotelikePost Options Post by icemandios on about an hour ago
When people talk about Wall Street these days, they are talking about unicorns and do-do birds.
There is no Wall Street. There are a multitude of exchanges and trading venues and dark pools. The NYSE is not even in NY. It's a bunker style building located in NJ. And the only people there are maintenance types who keep the servers running. The BS you see on CNBS is just for the amusement of the rubes.
So, Wall Street thinks this or that?
Is Ackman WS? Given his dual FU's with VRX and HLF, why should we care?
Is Soros WS? Given his loss of a billion bucks on the Trump election bets, why should we care?
Is Gartman WS? Need I go any farther?
There is no WS. It's a meme that is meant to carry meaning to those who don't know that WS ended many years ago. And for that, it was never anything but an enterprise to separate the gullible from their money. The game has just gotten more high tech and less transparent.
As the saying goes, WS has predicted 9 of the last 3 market turns.
Wall Street.......phoooey.
« Prev1Next »
Reply
Quick Reply
Font FaceFont Size
2 hours ago icemandios and thought013 like this ReplyQuoteEditlikePost Options Post by miamianne67 on 2 hours ago
New York Times
Business Day
WORLD U.S. N.Y. / REGION BUSINESS TECHNOLOGY SCIENCE HEALTH SPORTS OPINION ARTS STYLE TRAVEL JOBS REAL ESTATE AUTOS
Search
DealBookMarketsEconomyEnergyMediaTechnologyPersonal TechEntrepreneurshipYour Money
Big Board's Uncovered Short Sales Reach a High
By LAURENCE ZUCKERMAN
Published: August 20, 1994
GOOGLE+
SHARE
REPRINTS
Correction Appended
Short-selling is the opposite of buying a security in the hope that its price will rise; a short-seller borrows shares, sells them and later buys them back to return to the original owner. If the stock price drops, the trader profits because he can buy back the borrowed shares for less than he sold them. But if the stock rises, the trader loses when shares are repurchased. AT&T and Ford Among Leaders
Companies with the largest short positions on the New York Stock Exchange included RJR Nabisco Holdings, the Ford Motor Company, the AT&T Corporation and the Chrysler Corporation. Ford and AT&T were also among the stocks on the Big Board that showed the greatest monthly rise in short positions.
On the American Stock Exchange, the largest short positions included the Elan Corporation, the Ivax Corporation, XCL Ltd. and Turner Broadcasting System's class B shares.
An increase in short-selling activity has historically been regarded as an indication that stock prices will fall. But in recent years, more investors have used short positions as one element in multifaceted trading strategies. Some analysts even see rising uncovered short-selling positions as a positive sign, since the short-sellers must one day return to the market to buy the shares. Big Activity in Small Stock
The positions most difficult to cover are for those stocks that are sold short widely but are only thinly traded. For example, at the average number of shares traded last month, it would take about 150 trading days to cover the short position of Mark IV Industries, a maker of automotive and office equipment.
Some investors like to buy stocks with high cover ratios because they believe that investors with short positions will bid up the price of the shares when they enter the market to buy back the stock.
Other stocks with high cover ratios included Jan Bell Marketing, Elan and Cincinnati Gas and Electric.
cosomatic1
Full Member
***
cosomatic1 Avatar
Money: $550.00
Posts: 112Male
Posting Level
Next Level in 138 posts
2 hours ago miamianne67, icemandios, and 1 more like this ReplyQuotelikePost Options Post by cosomatic1 on 2 hours ago
I can't imagine who in there right mind would stay short at 7 and change. Thanks for the reminder on IVAX Miami. Good example how Dr. Frost can set them up...
miamianne67
Supreme Member
*****
miamianne67 Avatar
Money: $4,305.00
Posts: 840Female
Member is Online
Posting Level
Next Level in 160 posts
2 hours ago icemandios likes this ReplyQuoteEditlikePost Options Post by miamianne67 on 2 hours ago
Market Place; Expectations Cut, Ivax Drops $5.75
By Kurt Eichenwald
Published: December 22, 1992
GOOGLE+
SHARE
REPRINTS
AFTER more than a year of lofty promises for the the Ivax Corporation, expectations fell to earth yesterday as investors learned that the company's hot-selling drug was a little cooler than expected.
Ivax, a holding company for pharmaceutical and chemical businesses, was among the biggest losers yesterday on the American Stock Exchange, dropping $5.75 a share to close at $29.25 on volume of almost 1.7 million shares. It was the worst day in the stock's trading in its recent history.
What went wrong? Nothing much, really. There were no fundamental changes in its business or major disasters. Rather, the story behind Ivax's stock drop is one of rosy predications on Wall Street that prove impossible to meet.
While Wall Street frequently makes bad calls about stocks, Ivax is a special case. With the stock trading at some 69 times earnings and having about a $2.3 billion market capitalization at the close of trading on Friday, there was little to support a steep rise in its stock price other than the projection of its future business.
And no one on Wall Street pushed those projections further or harder than Ronald Nordmann, an analyst with Paine Webber, a firm that provides investment banking services to Ivax and whose specialist subsidiary makes a market in the stock. A large number of Wall Street traders and analysts said that no analyst or market participant had had greater influence on investors' attitudes toward Ivax than Mr. Nordmann.
"He has been the biggest bull on Wall Street on this stock," one analyst said. "He's got a pretty large following." A woman answering Mr. Nordmann's telephone yesterday said he was on vacation. He did not return telephone messages that she said had been relayed to him.
Mr. Nordmann worked hard on selling the Ivax story. Analysts say that when the company had troubles, Mr. Nordmann, who has wide respect within the pharmaceutical industry, won praise from his colleagues by being able to line up conference calls quickly between his clients and Ivax's management. That has won him admiration from competitors, investors and the company, none of whose attitudes seem dampened by the fact that Mr. Nordmann has been sued by investors in another stock he recommended who accused him of being over-optimistic.
Indeed, Mr. Nordmann's influence is so great that it was the news that he was cutting his quarterly earnings estimates for Ivax and reducing the company from a "buy" to an "attractive" rating that precipitated yesterday's selloff.
Among the only investors who do not appear to have been shocked by the change were Ivax insiders, who have been selling the stock heavily for months. Last month, almost 200,000 shares were sold by insiders, almost half of the total insider selling at the company for the entire year, according to David Coleman, editor of Vickers Weekly Insider Report. "At these prices, the insiders prefer the cash over the shares," he said.
Mr. Nordmann's overestimation on Ivax came from projections of its potential sales of its generic hypertension drug verapamil, a calcium channel blocker used once a day. The analyst had set goals for $50 million in sales of the drug this year -- higher than other analysts. In an interview in the fall, shortly after shipments began, Mr. Nordmann said that it would be "hard to believe" Ivax could miss that target.
It did. In his analysis yesterday, Mr. Nordmann cut back his estimates of verapamil sales to $40 million, citing long-term supply deals with managed-care organizations reached by G. D. Searle and Knoll, the makers of the brand name version of the drug. Those contracts, which were signed and delivered even before Ivax won approval for its drug, prevent those potential buyers from purchasing verapemil from Ivax.
This is not the first time Mr. Nordmann has been one of the most eager predictors of a company's performance before it disappointed. Both Paine Webber and Mr. Nordmann are still facing a six- year-old lawsuit charging the analyst with making overly positive comments about a stock that subsequently dropped sharply in value.
That lawsuit, filed in 1986, involved a recommendation made by the analyst to buy the stock of ICN Pharmaceuticals, another investment banking client of the firm. The company was testing a treatment for influenza, herpes and AIDS known as virazole, and in his report, Mr. Nordmann said the treatment "could become one of the largest-selling drugs in the world."
Mr. Nordmann's report in 1986 pushed up ICN's price from $18.875 to $33.375 in a week. After news reports at the time questioned his analysis, the stock fell significantly. In 1991, ICN paid $600,000 in costs and penalties after the Food and Drug Administration charged the company with misrepresenting the medicinal qualities of the drug. ICN stock traded yesterday at $6.375.
But Mr. Nordmann does not expect the Ivax story to be similar to that of ICN. In his analysis yesterday, the analyst said he remained "extremely enthusiastic," and that his new projections may prove too low. "We would rather have the opportunity to raise our estimates in the future," he wrote.
A lesson well learned.
Graph: "A Sudden Drop" tracks Ivax Corporation's stock price, monthly closings from 1990 through yesterday.
icemandios
Legendary
*
icemandios Avatar
Money: $16,380.00
Posts: 2,484Male
Posting Level
about an hour ago ReplyQuotelikePost Options Post by icemandios on about an hour ago
When people talk about Wall Street these days, they are talking about unicorns and do-do birds.
There is no Wall Street. There are a multitude of exchanges and trading venues and dark pools. The NYSE is not even in NY. It's a bunker style building located in NJ. And the only people there are maintenance types who keep the servers running. The BS you see on CNBS is just for the amusement of the rubes.
So, Wall Street thinks this or that?
Is Ackman WS? Given his dual FU's with VRX and HLF, why should we care?
Is Soros WS? Given his loss of a billion bucks on the Trump election bets, why should we care?
Is Gartman WS? Need I go any farther?
There is no WS. It's a meme that is meant to carry meaning to those who don't know that WS ended many years ago. And for that, it was never anything but an enterprise to separate the gullible from their money. The game has just gotten more high tech and less transparent.
As the saying goes, WS has predicted 9 of the last 3 market turns.
Wall Street.......phoooey.
« Prev1Next »
Reply
Quick Reply
Font FaceFont Size